Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences industry, this morning announced the
first major milestone achievement in its collaboration with the College of
Food, Agricultural, and Environmental Sciences (“CFAES”) of The Ohio State
University. According to the update, the program’s primary goal is to develop
and make available for commercialization a continuous-flow manufacturing
process to prepare foods and beverages with superior nutritional and sensory
qualities and long, room temperature shelf stability without the requirement
for refrigeration or chemical additives. The company believes that, through
scale-up of its innovative and patented Ultra Shear Technology(TM) (“UST”)
platform, it can achieve this highly sought-after consumer demand. “We are very
excited to have met this first major milestone. We believe our proprietary UST
platform can be used to make the higher quality, more nutritious,
longer-lasting foods that consumers now demand,” PBIO Sr. VP of Engineering Dr.
Edmund Y. Ting said in the news release. “The UST-based bench-top instrument –
together with the larger scale, floor model, higher capacity instrument we are
now developing – will be used to generate the fundamental food science quality
and safety validation data that we believe will enable future process adoption by
industry and acceptance by the regulators.”
To view the full press release, visit http://ibn.fm/rxN0b
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold,
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently-patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
